National Pension Service Cuts Stock Holdings in Eli Lilly and Company $LLY

National Pension Service reduced its position in Eli Lilly and Company (NYSE:LLY) by 5.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,543,238 shares of the company’s stock after selling 84,359 shares during the period. Eli Lilly and Company comprises approximately 1.0% of National Pension Service’s holdings, making the stock its 14th largest position. National Pension Service’s holdings in Eli Lilly and Company were worth $1,203,000,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company during the first quarter valued at $27,000. Blume Capital Management Inc. raised its position in Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares during the last quarter. IMG Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $35,000. TD Capital Management LLC grew its stake in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares during the period. Finally, Family CFO Inc purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $54,000. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on LLY shares. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Cantor Fitzgerald raised their price target on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Guggenheim reissued a “buy” rating and issued a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. Finally, DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $981.89.

Eli Lilly and Company Stock Performance

LLY opened at $987.48 on Wednesday. The firm has a market cap of $933.55 billion, a P/E ratio of 64.54, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $999.95. The company has a 50 day simple moving average of $809.69 and a two-hundred day simple moving average of $776.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the firm earned $1.18 EPS. The company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.